Eterna Therapeutics Inc.(ERNA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ERNA Eterna Therapeutics Inc.

Trading 05-08 12:19:24 EDT

6.70

-1.12

-14.33%

High8.11	Low6.61	Vol896.86K
Open7.69	D1 Closing7.82	Amplitude19.18%
Mkt Cap7.81M	Tradable Cap5.48M	Total Shares1.17M
T/O6.62M	T/O Rate109.64%	Tradable Shares817.98K
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"ERNA","market":"US","secType":"STK","nameCN":"Eterna Therapeutics Inc.","latestPrice":6.6997,"timestamp":1778257155404,"preClose":7.82,"halted":0,"volume":896860,"delay":0,"changeRate":-0.1432608695652174,"floatShares":817976,"shares":1166176,"eps":-55.890274,"marketStatus":"Trading","change":-1.1203,"latestTime":"05-08 12:19:24 EDT","open":7.69,"high":8.11,"low":6.61,"amount":6621137.11136,"amplitude":0.191816,"askPrice":6.75,"askSize":100,"bidPrice":6.61,"bidSize":50,"shortable":0,"etf":0,"ttmEps":-55.890274,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1778270400000},"marketStatusCode":2,"adr":0,"listingDate":465451200000,"exchange":"NASDAQ","adjPreClose":7.82,"preHourTrading":{"tag":"盘前","latestPrice":7.7,"preClose":7.82,"latestTime":"09:29 EDT","volume":114679,"amount":933195.087266,"timestamp":1778246999067,"change":-0.12,"changeRate":-0.015345,"amplitude":0.147059},"postHourTrading":{"tag":"盘后","latestPrice":8.19,"preClose":7.82,"latestTime":"19:59 EDT","volume":231542,"amount":1835088.404,"timestamp":1778198399061,"change":0.37,"changeRate":0.047315,"amplitude":0.149616},"volumeRatio":0.137957},"requestUrl":"/m/hq/s/ERNA/wiki","defaultTab":"wiki","newsList":[{"id":"2633087171","title":"Ernexa Therapeutics initiated with a Buy at Brookline","url":"https://stock-news.laohu8.com/highlight/detail?id=2633087171","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633087171?lang=en_us&edition=fundamental","pubTime":"2026-05-08 05:58","pubTimestamp":1778191090,"startTime":"0","endTime":"0","summary":"Brookline initiated coverage of Ernexa Therapeutics (ERNA) with a Buy rating and $30 price target Ernexa is engineering induced pluripotent stem ce...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/ernexa-therapeutics-initiated-with-a-buy-at-brookline-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/ernexa-therapeutics-initiated-with-a-buy-at-brookline-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BRKL","BK4007","LENZ","BK4211","BK4139","BK4539","ERNA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633195262","title":"Ernexa Therapeutics announces new ERNA-101 preclinical data","url":"https://stock-news.laohu8.com/highlight/detail?id=2633195262","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633195262?lang=en_us&edition=fundamental","pubTime":"2026-05-07 12:27","pubTimestamp":1778128039,"startTime":"0","endTime":"0","summary":"Ernexa Therapeutics (ERNA) announced new preclinical data demonstrating that its lead cell therapy candidate, ERNA-101, in combination with PD-1 bl...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/ernexa-therapeutics-announces-new-erna-101-preclinical-data-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/ernexa-therapeutics-announces-new-erna-101-preclinical-data-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","ERNA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633139866","title":"NASDAQ TRADE HALT  VOLATILITY TRADING PAUSE AT 09:34 AM","url":"https://stock-news.laohu8.com/highlight/detail?id=2633139866","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633139866?lang=en_us&edition=fundamental","pubTime":"2026-05-06 21:34","pubTimestamp":1778074485,"startTime":"0","endTime":"0","summary":"NASDAQ TRADE HALT  VOLATILITY TRADING PAUSE AT 09:34 AM","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260506:nAQN2LXV0B:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ERNA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633412133","title":"Ernexa reports ERNA-101 plus PD-1 blockade clears tumors in ovarian cancer models","url":"https://stock-news.laohu8.com/highlight/detail?id=2633412133","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633412133?lang=en_us&edition=fundamental","pubTime":"2026-05-06 20:33","pubTimestamp":1778070839,"startTime":"0","endTime":"0","summary":"Ernexa Therapeutics on May 6, 2026 reported new preclinical results for lead cell therapy candidate ERNA-101 used with PD-1 blockade in ovarian cancer models; results were presented with this announcement.Combination treatment produced complete tumor elimination in tested models, outperforming either approach alone.Studies showed durable long-term survival in treated animals, supporting a potential curative profile in these models.Data point to tumor microenvironment remodeling that could make checkpoint inhibitors more effective in immunologically “cold” tumors.Program positioned to support a first-in-human study in advanced ovarian cancer, with additional combination work underway to broaden potential solid-tumor use.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260506:nNDL1T7bgP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","IE00B3QW5Z07.USD","IE00BN0W2V16.EUR","BK4585","BK4139","IE00BKPKM429.USD","LU2095319765.USD","SG9999014013.SGD","SG9999014005.SGD","NDAQ","LU0314104364.USD","IE00BGHQF748.EUR","BK4112","LU2210149790.SGD","IE00B64PRP62.GBP","SG9999014021.USD","LU2210150020.SGD","SG9999014039.USD","ERNA","IE00BN0W2W23.USD","IE00BN0W2T93.GBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632601336","title":"NASDAQ TRADE HALT  HALT NEWS PENDING AT 03:28 AM","url":"https://stock-news.laohu8.com/highlight/detail?id=2632601336","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632601336?lang=en_us&edition=fundamental","pubTime":"2026-05-03 15:28","pubTimestamp":1777793303,"startTime":"0","endTime":"0","summary":"NASDAQ TRADE HALT  HALT NEWS PENDING AT 03:28 AM","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260503:nAQN2LXFUT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ERNA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631630163","title":"Ernexa Therapeutics Announces 1-for-25 Reverse Stock Split","url":"https://stock-news.laohu8.com/highlight/detail?id=2631630163","media":"GlobeNewswire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631630163?lang=en_us&edition=fundamental","pubTime":"2026-04-30 21:00","pubTimestamp":1777554000,"startTime":"0","endTime":"0","summary":"CAMBRIDGE, Mass., April  30, 2026 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), an industry innovator developing novel cell therapies for the treatment of advanced cancer and autoimmune dise","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/04/30/3284944/0/en/Ernexa-Therapeutics-Announces-1-for-25-Reverse-Stock-Split.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","LENZ","BK4139","ERNA","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627568974","title":"Ernexa Therapeutics authorizes 1-for-10 to 1-for-25 reverse stock split to meet Nasdaq bid rule","url":"https://stock-news.laohu8.com/highlight/detail?id=2627568974","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627568974?lang=en_us&edition=fundamental","pubTime":"2026-04-13 21:29","pubTimestamp":1776086944,"startTime":"0","endTime":"0","summary":"Ernexa board adopted reverse stock split resolutions March 26, 2026.Majority shareholder written consent received March 27, 2026, covering 15,552,343 shares, or 53.3% voting power.Action authorizes board to set reverse split ratio within 1-for-10 to 1-for-25.Move targets Nasdaq minimum bid price rule requiring $1 per share for continued listing.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ernexa Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 13, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260413:nNDL8jsR0s:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ERNA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624447965","title":"Ernexa Therapeutics files draft information statement for potential reverse stock split","url":"https://stock-news.laohu8.com/highlight/detail?id=2624447965","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624447965?lang=en_us&edition=fundamental","pubTime":"2026-04-02 05:23","pubTimestamp":1775078626,"startTime":"0","endTime":"0","summary":"Ernexa shareholders authorized board to execute reverse stock split at ratio set between 1-for-10 and 1-for-25.Move targets higher share price to meet Nasdaq $1 minimum bid requirement.Outstanding common shares totaled about 29.2 million as of March 27, 2026.Reverse split would leave authorized common stock unchanged at 150 million shares.Board plans to round up fractional positions to nearest whole share.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ernexa Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 01, 2026, and is solely responsible for the information con","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260401:nNDL3zT6s4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ERNA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623580331","title":"Ernexa Therapeutics Highlights Key Catalysts as Company Advances Toward First-in-Human Clinical Trials in 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2623580331","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623580331?lang=en_us&edition=fundamental","pubTime":"2026-03-31 20:55","pubTimestamp":1774961700,"startTime":"0","endTime":"0","summary":"Preclinical data demonstrate deep and durable tumor regressions with lead product candidate ERNA-101 in combination with PD-1 Blockade in ovarian cancer IND submission for ERNA-101 expected in Q3 2026","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/03/31/3265550/0/en/Ernexa-Therapeutics-Highlights-Key-Catalysts-as-Company-Advances-Toward-First-in-Human-Clinical-Trials-in-2026.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ERNA","BK4139","BK4007","LENZ","BK4539","IND"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621419754","title":"Ernexa Therapeutics faces Nasdaq delisting notice after bid price falls below $1 for 30 days","url":"https://stock-news.laohu8.com/highlight/detail?id=2621419754","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621419754?lang=en_us&edition=fundamental","pubTime":"2026-03-21 05:01","pubTimestamp":1774040499,"startTime":"0","endTime":"0","summary":"Ernexa received a Nasdaq notice stating it failed to maintain a minimum bid price of $1.00 per share for 30 consecutive business days under Listing Rule 5550.Nasdaq staff said the company is not eligible for the typical 180-day compliance period because it completed a reverse stock split within the prior year.The company plans to request a hearing before the Nasdaq Hearing Panel, which would stay any suspension or delisting action while the hearing process is pending.The panel can grant an extension of up to 180 days from the notice date for the company to regain compliance.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ernexa Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic D","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"ab6e84fb0542480d9cf75cb6a9fe5601","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260320:nNDL8Z5lTQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ERNA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619545253","title":"Ernexa Therapeutics files $50M mixed securities shelf","url":"https://stock-news.laohu8.com/highlight/detail?id=2619545253","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619545253?lang=en_us&edition=fundamental","pubTime":"2026-03-16 18:56","pubTimestamp":1773658594,"startTime":"0","endTime":"0","summary":"06:51 EDT Ernexa Therapeutics (ERNA) files $50M mixed securities shelf Published first on TheFly – the ultimate source for real-time, market-moving...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/ernexa-therapeutics-files-50m-mixed-securities-shelf-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/ernexa-therapeutics-files-50m-mixed-securities-shelf-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ERNA","BK4007","LENZ","BK4139","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619445901","title":"BRIEF-Ernexa Therapeutics Inc - May Offer Up To $50 Million Of Securities - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2619445901","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619445901?lang=en_us&edition=fundamental","pubTime":"2026-03-16 18:06","pubTimestamp":1773655571,"startTime":"0","endTime":"0","summary":"BRIEF-Ernexa Therapeutics Inc - May Offer Up To $50 Million Of Securities - SEC FilingMarch 16  - Ernexa Therapeutics Inc ERNA.O:ERNEXA THERAPEUTICS INC - MAY OFFER UP TO $50 MILLION OF SECURITIES - SEC FILINGSource text: [ID:n0001493152-26-010128]Further company coverage: ERNA.O ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260316:nFWN40304Y:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ERNA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619459222","title":"Ernexa Therapeutics Inc - May Offer up to $50 Mln of Securities - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2619459222","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619459222?lang=en_us&edition=fundamental","pubTime":"2026-03-16 18:01","pubTimestamp":1773655300,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260316:nFWN40304Y:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ERNA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619431481","title":"Ernexa Therapeutics FY 2025 net loss narrows 68% to USD 14.08 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2619431481","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619431481?lang=en_us&edition=fundamental","pubTime":"2026-03-14 05:23","pubTimestamp":1773436983,"startTime":"0","endTime":"0","summary":"Ernexa reported no revenue for FY 2025 and a net loss of USD 14.08 million, a 68% narrowing from the prior year. Loss from operations was USD 9.32 million, a 41% improvement, as total operating expenses fell 42% to USD 9.32 million. Research and development expense decreased 10% to USD 4.16 million, primarily due to lower MSA/license fees and payroll-related costs, partially offset by higher consulting and study fees. General and administrative expense declined 61% to USD 5.16 million, mainly reflecting lower occupancy costs after terminating its Somerville sublease and reduced legal and consulting fees. Ernexa ended FY 2025 with cash of USD 1.9 million, and management said it expects it will not have sufficient capital to fund operations for the 12 months following issuance of the financial statements.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260313:nNDL5XPP6z:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ERNA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2612267745","title":"Ernexa Therapeutics CEO Sanjeev Luther to Join Virtual Investor Closing Bell Series Webcast","url":"https://stock-news.laohu8.com/highlight/detail?id=2612267745","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612267745?lang=en_us&edition=fundamental","pubTime":"2026-02-20 22:05","pubTimestamp":1771596311,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ernexa Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire  on February 20, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260220:nNDL2nmjv9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B64PRP62.GBP","BK4139","LU0314104364.USD","LU2210149790.SGD","LU2210150020.SGD","SG9999014005.SGD","SG9999014013.SGD","IE00BGHQF748.EUR","SG9999014039.USD","NDAQ","LU2095319765.USD","IE00B3QW5Z07.USD","BK4588","BK4585","ERNA","IE00BKPKM429.USD","SG9999014021.USD","BK4112"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2612924484","title":"10% Owner Charles Cherington Reports Acquisition of Ernexa Therapeutics Inc. Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2612924484","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612924484?lang=en_us&edition=fundamental","pubTime":"2026-02-18 10:15","pubTimestamp":1771380913,"startTime":"0","endTime":"0","summary":"Charles Cherington, a 10% owner, reported the acquisition of common shares of Ernexa Therapeutics Inc. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ernexa Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on February 17, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260218:nNDL2YFxhK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"10% Owner Charles Cherington Reports Acquisition of Ernexa Therapeutics Inc. Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ERNA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2610642259","title":"Ernexa Therapeutics Announces Issuance of Warrants in $10.5 Million Public Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2610642259","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610642259?lang=en_us&edition=fundamental","pubTime":"2026-02-12 06:11","pubTimestamp":1770847868,"startTime":"0","endTime":"0","summary":"Ernexa Therapeutics Inc. has announced the pricing of a public offering consisting of 21,000,000 shares of its common stock  and warrants to purchase up to 21,000,000 shares of common stock. The combined public offering price is $0.50 per share and accompanying warrant. The warrants have an exercise price of $0.68 per share, are exercisable upon issuance, and will expire on the earlier of five years from the issuance date or 180 days after the public release of clinical trial data from the first cohort of the Phase 1 study of ERNA-101. The gross proceeds from the offering are expected to be approximately $10.5 million, with potential additional proceeds of $14.3 million if all warrants are exercised. Ernexa intends to use the net proceeds to advance its development programs, for working capital, and for general corporate purposes.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260211:nNDL9rps2n:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ERNA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2609594170","title":"Ernexa Therapeutics prices 21M shares at 50c in public offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2609594170","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609594170?lang=en_us&edition=fundamental","pubTime":"2026-02-06 22:30","pubTimestamp":1770388230,"startTime":"0","endTime":"0","summary":"Ernexa Therapeutics (ERNA) announced the pricing of a best-efforts registered public offering of 21,000,000 shares of its common stock and warrants...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/ernexa-therapeutics-prices-21m-shares-at-50c-in-public-offering-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/ernexa-therapeutics-prices-21m-shares-at-50c-in-public-offering-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ERNA","BK4007","LENZ","BK4139","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2609594329","title":"Ernexa Therapeutics Announces Pricing of $10.5 Million Public Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2609594329","media":"GlobeNewswire","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609594329?lang=en_us&edition=fundamental","pubTime":"2026-02-06 22:25","pubTimestamp":1770387900,"startTime":"0","endTime":"0","summary":"CAMBRIDGE, Mass., Feb.  06, 2026  (GLOBE NEWSWIRE) -- Ernexa Therapeutics Inc. (Nasdaq: ERNA) (“Ernexa” or the “Company”), an industry innovator developing novel cell therapies for the treatment of ad","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/02/06/3233873/0/en/Ernexa-Therapeutics-Announces-Pricing-of-10-5-Million-Public-Offering.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4539","BK4007","ERNA","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2608874147","title":"Ernexa Therapeutics Participates in Virtual Investor “What This Means” Segment Highlighting Recent Successful Pre-IND Meeting with U.S. FDA","url":"https://stock-news.laohu8.com/highlight/detail?id=2608874147","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608874147?lang=en_us&edition=fundamental","pubTime":"2026-02-03 21:45","pubTimestamp":1770126300,"startTime":"0","endTime":"0","summary":"Access the “What This Means” segmenthere CAMBRIDGE, Mass., Feb.  03, 2026  (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), an industry innovator developing novel cell therapies for the treatme","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/02/03/3231107/0/en/Ernexa-Therapeutics-Participates-in-Virtual-Investor-What-This-Means-Segment-Highlighting-Recent-Successful-Pre-IND-Meeting-with-U-S-FDA.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4007","IND","BK4539","ERNA","LENZ"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.ernexatx.com","stockEarnings":[{"period":"1week","weight":1.1192},{"period":"1month","weight":0.4617},{"period":"3month","weight":-0.1687},{"period":"6month","weight":-0.8213},{"period":"1year","weight":-0.8993},{"period":"ytd","weight":-0.7393}],"compareEarnings":[{"period":"1week","weight":0.018},{"period":"1month","weight":0.1098},{"period":"3month","weight":0.0593},{"period":"6month","weight":0.0903},{"period":"1year","weight":0.3037},{"period":"ytd","weight":0.0728}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Eterna Therapeutics Inc., a life science company, provides mRNA cell engineering technologies. Its technologies include mRNA cell reprogramming and gene editing; NoveSlice and UltraSlice gene-editing proteins; and the ToRNAdo mRNA delivery system. The company has a license agreement with Factor Bioscience Limited. Eterna Therapeutics Inc. was founded in 2018 and is based in Cambridge, Massachusetts.","yearOnYearQuotes":[{"month":1,"riseRate":0.558824,"avgChangeRate":0.130666},{"month":2,"riseRate":0.382353,"avgChangeRate":-0.039626},{"month":3,"riseRate":0.558824,"avgChangeRate":0.018953},{"month":4,"riseRate":0.352941,"avgChangeRate":0.335049},{"month":5,"riseRate":0.411765,"avgChangeRate":-0.006724},{"month":6,"riseRate":0.515152,"avgChangeRate":0.017044},{"month":7,"riseRate":0.264706,"avgChangeRate":-0.033365},{"month":8,"riseRate":0.411765,"avgChangeRate":-0.028873},{"month":9,"riseRate":0.323529,"avgChangeRate":-0.027842},{"month":10,"riseRate":0.352941,"avgChangeRate":-0.041231},{"month":11,"riseRate":0.5,"avgChangeRate":0.055021},{"month":12,"riseRate":0.323529,"avgChangeRate":-0.050712}],"exchange":"NASDAQ","name":"Eterna Therapeutics Inc.","nameEN":"Eterna Therapeutics Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.1","shortVersion":"4.42.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Eterna Therapeutics Inc.(ERNA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Eterna Therapeutics Inc.(ERNA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Eterna Therapeutics Inc.,ERNA,Eterna Therapeutics Inc.股票,Eterna Therapeutics Inc.股票老虎,Eterna Therapeutics Inc.股票老虎国际,Eterna Therapeutics Inc.行情,Eterna Therapeutics Inc.股票行情,Eterna Therapeutics Inc.股价,Eterna Therapeutics Inc.股市,Eterna Therapeutics Inc.股票价格,Eterna Therapeutics Inc.股票交易,Eterna Therapeutics Inc.股票购买,Eterna Therapeutics Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Eterna Therapeutics Inc.(ERNA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Eterna Therapeutics Inc.(ERNA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}